Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
2021年7月16日 更新者:Jiangsu HengRui Medicine Co., Ltd.
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of New Formulation SHR-1316 in Subjects With Advanced Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the new formulation SHR-1316 in subjects with advanced tumors.
調査の概要
研究の種類
介入
入学 (予想される)
15
段階
- フェーズ 1
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Wen Jing
- 電話番号:17721286191
- メール:wen.jing@hengrui.com
研究連絡先のバックアップ
- 名前:Yuya Wang
- 電話番号:13918749176
- メール:yuya.wang@hengrui.com
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Age ≥18 years.
- Histologically or cytologically confirmed advanced cancer in patients who are fail to current standard therapy or lack of effective therapy.
- Estimated life expectancy ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ functions.
- If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment dose.
- Patients must be willing and able to provide written informed consent prior to the performance of any study-specific procedure.
Exclusion Criteria:
- Known history of hypersensitivity to any components of the SHR-1316 product.
Patient- Prior treatment with the following agents:
- "Check-point inhibitors", including Programmed death receptor-1 (PD-1), PD-L1;
- Receipt of investigational agents within 4 weeks prior to study treatment;
- Current treatment on another therapeutic clinical trial, unless the observational (non-interventional) clinical trials or follow-up of interventional clinical trials;
- Any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, target therapy, biotherapy or tumor embolization), administered within 4 weeks prior to study treatment; or within 6 weeks in the case of certain therapies (e.g., mitomycin C and nitrosoureas). Any such, unless discussed and explained with the sponsor;
- Anticipated need for any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, or biotherapy) during SHR-1316 treatment; except palliative radiotherapy;
- Receipt of any anti-cancer vaccines; receipt of immunomodulatory drugs within 4 weeks prior to study treatment; topical, nasal spray and inhaled corticosteroids as well as systemic steroid therapy in physiological doses (such as: prednisone ≤10 mg/day) are acceptable.
- Patients have unrecovered (ie, to NCI CTCAE grade ≤1) from all toxicity associated with previous treatments (exception: patients may enter with continuing alopecia irrespective of CTCAE grade; grade 2 peripheral nerve diseases).
- Known Active central nervous system (CNS) metastases; Patients who had previously received brain or meningeal metastasis therapy, who were clinically stable for at least 8 weeks, and who had stopped systemic sex hormone therapy (such as: prednisone > 10 mg/day) for more than 4 weeks were included.
- Subjects with active autoimmune disease, history of autoimmune diseases, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.
- Active or history of immune deficiency, such as human immunodeficiency virus (HIV) infection; History of organ transplantation.
- History or evidence of cardiovascular (CV) risk including any of the following: Congestive heart failure (Class >2) as defined by the New York Heart Association functional classification system (NYHA), unstable angina pectoris, Recent (within the past 12 months) history of myocardial infarction, clinically significant supraventricular or ventricular arrhythmias need treatment or intervention.
- Patients with clinically significant ECG abnormalities (QT interval corrected for rate by Fridericia's formula [QTcF] >470 msec for female and >450 msec for male on the ECG obtained at Screening).
- Active infection that need drug intervention or an unexplained fever >38.5°C (fever caused by cancer can be included according to the judgement of the researcher).
- Active pulmonary tuberculosis infection.
- Positive for Hepatitis B or C.
- Known history of psychoactive drug abuse, alcohol abuse or drug use.
- Known history of any other malignant cancer within past 3 years. Exceptions: completely resected basal cell carcinoma and squamous cell carcinoma of the skin; and completely resected carcinoma in situ of cervix.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:治療群
|
SHR-1316 administrated intravenously (IV) at protocol defined dose levels
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Maximum plasma concentration (Cmax)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Time to maximum concentration (Tmax)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Area under the concentration-time curve from time zero to time(AUC0-t)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Area under the concentration-time curve extrapolated to infinity (AUC0-∞.)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Elimination half-life (t1/2)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Clearance (CL)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Volume of distribution (Vz)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Trough concentration (Cmin)
時間枠:approximately 1 year
|
approximately 1 year
|
|
Accumulatio of ratio (Rac)
時間枠:approximately 1 year
|
approximately 1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Immunogenicity of SHR-1316
時間枠:approximately 1 year
|
Anti-SHR-1316 antibody (ADA), neutralizing antibody (Nab)
|
approximately 1 year
|
|
Objective response rate (ORR)
時間枠:approximately 1 year
|
approximately 1 year
|
|
|
Progression-free survival (PFS)
時間枠:approximately 1 year
|
approximately 1 year
|
|
|
Duration of response (DoR)
時間枠:approximately 1 year
|
approximately 1 year
|
|
|
Disease control rate (DCR)
時間枠:approximately 1 year
|
approximately 1 year
|
|
|
Overall survival (OS)
時間枠:approximately 1 year
|
approximately 1 year
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (予想される)
2021年8月10日
一次修了 (予想される)
2022年2月10日
研究の完了 (予想される)
2022年7月31日
試験登録日
最初に提出
2021年7月12日
QC基準を満たした最初の提出物
2021年7月16日
最初の投稿 (実際)
2021年7月28日
学習記録の更新
投稿された最後の更新 (実際)
2021年7月28日
QC基準を満たした最後の更新が送信されました
2021年7月16日
最終確認日
2021年7月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- SHR-1316-I-103
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。